Predictive Factors of Tumor Recurrence after Radical Surgery for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs): Identification of High-Risk Subgroups Abstract #2784

Introduction: There is no proven role for adjuvant medical therapy after curative surgery (R0) for GEP-NENs.
Aim(s): To evaluate predictive factors of tumor recurrence after radical surgery.
Materials and methods: Data from histologically confirmed G1-G2 GEP-NENs patients who underwent R0 surgery over the last 10 years were retrospectively analyzed. Site of the primary tumor, grading, staging, presence of positive lymph-nodes (N+), angio-neuro and parenchymal invasion were evaluated.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Roberta Elisa Rossi

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2700 Pancreatic Neuroendocrine Neoplasms and Liver Metastases: When Size Matters
Introduction: Small non-functioning pNENs are low grade indolent tumors, however distant metastases have also been documented in this subset of patients
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Michela Monteleone
#2716 Neuroendocrine Carcinoma of the Upper Urinary Tract: A Case Report
Introduction: There are no dedicated guidelines for treatment of urothelial NEC given disease rarity. An aggressive approach, including neoadjuvant cisplatin-based chemotherapy + nephroureterectomy and adjuvant platinum-based chemotherapy, is recommended.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Roberta Elisa Rossi
#2724 Overall Survival and Progression Free Survival of Patients with Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV
Introduction: Large cell neuroendocrine cancer (LCNEC) is characterized rare incidence and poor prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Anna Łowczak
#2725 Upfront Surgery in Patients with High-Grade GEP NEN and MINEN: A Nordic Multicenter Study of 201 Patients
Introduction: Surgery is the principal treatment for loco-regional gastroenteropancreatic (GEP) neuroendocrine tumors (NET). However, whether surgery is beneficial in high-grade neuroendocrine neoplasms (NEN) and mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN) is not known.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD, PhD Hans-Christian Pommergaard
#2736 Second Primary Neoplasms in Patients with Neuroendocrine Neoplasms (NEN): DATA from a Retrospective Multicentric Study
Introduction: Patients with sporadic gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) may exhibit a higher risk of second primary tumors than the general population.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: dr Sara Massironi